A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Inclusion Criteria:

• Patients receiving faricimab according to the local faricimab product label and whohave initiated treatment with faricimab at time of the ICF signature date or no morethan 3 months prior to the ICF signature date, in diabetic macular edema (DME) orneovascular age-related macular degeneration (nAMD) in at least one eye

• Patients have received at least one faricimab treatment (the first dose) in thestudy eye

• Patients should have available data for visual acuity (VA) and Central SubfieldThickness (CST) for the Baseline level (i.e. examinations to be performed at theindex date or within 4 months prior to it)

Exclusion Criteria:

• Patient participation in any investigational ophthalmology clinical trial thatincludes receipt of any ophthalmological investigational drug or procedure withinthe last 28 days prior to the ICF signature date

• Concomitant participation in any interventional clinical study

• Active ocular inflammation and/or suspected/active ocular infection in either eye

• Patients treated with faricimab who have and are currently participating in patientsupport programs (PSP) that are Market Research and Patient Support Programs (MAP)including Post Trial Access Programs (PTAP) and Compassionate Use Programs (CUP)

• Patients with non-ocular sight threatening disease which have an effect on theprimary endpoint (e.g., apoplexia)

• Hypersensitivity to the active substance or any of the excipients of Vabysmo (as perlabel)